Stem cell-based photodynamic therapy by Shrestha, Tej Bahadur et al.
This is the author’s final, peer-reviewed manuscript as accepted for publication.  The 
publisher-formatted version may be available through the publisher’s web site or your 
institution’s library.  
This item was retrieved from the K-State Research Exchange (K-REx), the institutional 
repository of Kansas State University.  K-REx is available at http://krex.ksu.edu 
 
Stem cell-based photodynamic therapy 
 
Tej B. Shrestha, Gwi M. Seo, Matthew T. Basel, Mausam Kalita, Hongwang Wang, 
David Villanueva, Marla Pyle, Deryl L. Troyer, and Stefan H. Bossmann 
 
 
How to cite this manuscript 
 
If you make reference to this version of the manuscript, use the following information: 
 
Shrestha, T. B., Seo, G. M., Basel, M. T., Kalita, M., Wang, H., Villanueva, D., . . . 
Bossmann, S. H. (2012). Stem cell-based photodynamic therapy. Retrieved from 
http://krex.ksu.edu 
 
 
Published Version Information 
 
 
Citation: Shrestha, T. B., Seo, G. M., Basel, M. T., Kalita, M., Wang, H., Villanueva, D., 
. . . Bossmann, S. H. (2012). Stem cell-based photodynamic therapy. Photochemical & 
Photobiological Sciences, 11(7), 1251-1258. 
 
 
 
Copyright: © The Royal Society of Chemistry and Owner Societies 2012 
 
 
 
Digital Object Identifier (DOI): doi:10.1039/c2pp05417e 
 
 
 
Publisher’s Link: http://pubs.rsc.org/en/Content/ArticleLanding/2012/PP/c2pp05417e 
 
 
 
Cite this: DOI: 10.1039/c0xx00000x 
www.rsc.org/xxxxxx Full Article
 
This journal is © The Royal Society of Chemistry [year] [journal], [year], [vol], 00–00  |  1 
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We have transfected murine neural stem cells (NSCs) with a plasmid expressing Gaussia luciferase 
(gLuc). The enzyme is secreted from the cells. We have used the gLuc-containing supernatant from 
cultured NSCs to perform in vitro photodynamic therapy of murine melanoma cells (B16F10). The 
treatment system was comprised of 5-aminolevulinic acid as a prodrug for the synthesis of the 10 
photosensitizer protoporphyrin IX, Gaussia luciferase, and its substrate, coelenterazine. A significant 
reduction in the number of live melanoma cells was observed 36h after coelenterazine-mediated PDT. 
Introduction 
In the search for new cancer treatment methods able to overcome 
the multi-drug resistance found in many cancer types, it will be 15 
advantageous to try new approaches. Classic chemotherapy 
focuses on killing cells that are dividing rapidly. Unfortunately, 
many other cells in the body also divide rapidly, causing many of 
well-known chemotherapy side effects (e.g. fatigue from low red 
blood cell count, susceptibility to infection from wiping out the 20 
white blood cells, and weight loss because of the lack of 
functioning intestinal cells).1,2 Classic chemotherapy often fails 
because these side effects prevent administering doses of these 
anticancer drugs adequate to kill the tumour cells. 
Photodynamic therapy (PDT) has been successful in treating non-25 
hypoxic tumours, which were conveniently located to permit high 
doses of incident light.3 To date, the U.S. Food and Drug 
Administration (FDA) has approved the photo-sensitizing agent 
porfimer sodium (Photofrin®), for use in PDT for the treatment 
of esophageal cancer4, non-small cell lung cancer4 and of 30 
precancerous lesions in patients with Barrett’s esophagus (a 
condition that can lead to esophageal cancer). The main obstacle 
to a prevalent application of PDT is not the enrichment of 
photodynamic drugs within tumours, but the availability of light 
sources that provide sufficiently high doses in the appropriate 35 
excitation windows for mono-photonic and bi/multi-photonic 
excitation. The light absorption coefficients of water and human 
aorta tissue possess a minimum region of tissue absorption at 
800±50nm. This corresponds to maximal light penetration depths 
()5 of 1cm at 800nm, 0.5cm at 600nm and 900nm, and 0.1cm at 40 
400nm.5,6 Numerous strategies for enhanced irradiation of 
tumours that are located within the human or mammalian body 
are discussed in the literature.7 Among these approaches are the 
use of high-energy lasers instead of lamps7, laser diodes8, fiber-
optical devices for the in situ irradiation of the interstitium9, the 45 
use of gold nanoshells and nanocages as high absorption and 
scattering materials10, and bi- and multi-photon excitation of 
suitable chromophores.11 Bi- and multiphoton absorption offers 
the advantage of spatially resolved irradiation and higher 
selectivity than mono-photonic excitation, especially when 50 
femtosecond pulses are used.11 However, the light intensities 
required for the simultaneous absorption of two or several 
photons are very hard to achieve when treating tumours within 
the human/mammalian body, because the two- and multi-photon 
absorption cross-sections are generally low.11  55 
Early detection of tumours and especially their metastases is 
crucial for cancer treatment. Traditionally, tumour detection is 
achieved by various methods, including magnetic resonance 
imaging and computerized tomography. The recent advances in 
life science and bioengineering permit the transfection, cellular 60 
expression, and real-time imaging of light-emitting proteins, such 
as Renilla luciferase (Ruc), bacterial luciferase (Lux), or 
fluorescent proteins, such as firefly luciferase (Luc), green 
fluorescent protein (GFP), or Ruc-GFP fusion protein.12 All of 
these marker proteins, which generate bioluminescence by 65 
chemical processes12, have been successfully employed for 
tumour detection. Since no excitation light is required, there is no 
background fluorescence and, consequently, a much improved 
signal to noise ratio. It has also been demonstrated that certain 
bacteria (e.g. Clostridium and Bifidobacterium13), viruses14, and 70 
neural stem cells15, when administered systemically, are able to 
gain entry to and replicate selectively in tumours. In addition 
many tissue/tumour specific promoters have been cloned, 
allowing transgene expression specifically in tumour tissues.16 
Here we describe the transfection of murine neural stem cells 75 
with Gaussia luciferase. Gaussia, a calanoid copepod, about 
6mm in size, is a member of the planktonic community. Gaussia 
luciferase has a molecular weight of only 19.9 kDA, which makes 
it the smallest luciferase using coelenterazine as substrate.17-19 It 
is noteworthy that Gaussia luciferase is approx. 750-fold brighter 80 
than native Renilla luciferase (when consuming the same amount 
of substrate).20 In the work reported here, neural stem cells 
secreting Gaussia luciferase were cultured. Murine B16F10 
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melanoma cells were then treated with the resulting culture 
medium containing Gaussia luciferase and its substrate 
coelenterazine (COEL).16-19 ALA (5-aminolevulinic acid) was 
given to the B16F10 cells prior to PDT. ALA is the prodrug for 
the biosynthesis of the photosensitizer protoporphyrin IX (PpIX) 5 
in the cancer cells’ mitochondria.21,22 The effects all three 
components (ALA, COEL, and bioluminescence alone) on the 
cancer cells as a function of time is discussed in this report. The 
structures of ALA, protoporphyrin IX, and coelenterazine are 
shown in Scheme 1. 10 
 
Scheme 1: Structures of aminolevulinic acid (1), protoporphyrin IX (2) 
and coelenterazine (3). 
Results and Discussion 
The first attempt to use bioluminescence from NIH 3T3 murine 15 
fibroblasts, which were transfected with firefly luciferase, was 
reported in 2003 by A. J. MacRobert and coworkers.23 The cells 
were loaded with D-luciferin and the photosensitizer rose bengal 
featuring a quantum yield of singlet-oxygen sensitization of 
=0.75±0.05 in aqueous media.23 The emission spectrum of 20 
luciferase/ATP oxyluciferin and the absorption spectrum of rose 
bengal match very nicely. In such a case, the excitation of rose 
bengal can be achieved by either reabsorption of the 
bioluminescence or through Förster energy transfer.24 
The bioluminescence from firefly luciferase requires D-luciferin 25 
and ATP. In the presence of luciferase, D-luciferin and rose 
bengal, the cell survival rate dropped from 100% to 11% after 
24h.23 Although this initial study demonstrated the potential of in 
situ PDT, it had the following drawbacks with respect to possible 
in vivo applications: 1) the cell that is to be treated has to be 30 
transfected with the gene of a bioluminescent enzyme first; and 2) 
rose bengal is a very good sensitizer for technical applications, 
such as vitamin D synthesis25, however, it is toxic to cells.26 A 
suitable therapeutic system should comprise a non-toxic 
sensitizer and cells that are able to migrate to solid tumours and 35 
secrete the bioluminescent enzyme. The singlet oxygen 
sensitization by the sensitizer should be sufficient to permit the 
efficient generation of singlet oxygen, even in the usually 
hypoxic tumour environment. 
 40 
A Neural Stem Cell-Based in Vitro System for Photodynamic 
Therapy of Melanoma 
Mouse neural stem cells (C17.2 immortalized cells) were 
transfected with a plasmid containing the gene for Gaussia 
luciferase  (Nanolight).27 Mouse neural stem cells (NSC) were 45 
used because they are known to “home” to numerous solid 
tumours.15 The pGLuc-basic-1 vector contains the "humanized" 
coding sequence for secreted Gaussia luciferase (gLuc), for use 
in mammalian cells. The medium containing gLuc secreted from 
the C17.2 cells was harvested at 24 hours and used to treat 50 
B16F10 mouse melanoma cells that had been independently 
cultured and treated with the supernatant from the mouse neural 
stem cells. Figure 1 shows the cell cultures of the mouse neural 
stem cells (A) and B16F10 mouse melanoma cells (B).  
 55 
Figure 1: A: C17.2 neural stem cells (mouse NSC)), 20x magnification; 
B: B16F10 melanoma cells, 20x magnification. 
The emission spectrum of the bioluminescence emitted from the 
supernatant in the presence of coelenterazine is shown in Figure 
2. The bioluminescence occurs during the oxidation of 60 
coelenterazine to coelenteramide by gLuc, as shown in Scheme 2. 
 
Figure 2: Emission from gLuc: 2mL of supernatant from the medium in 
which gLuc transfected neural stem cells (NSC) have been grown for 24h, 
to which was added 8 µl of  coelenterazine (1mg/mL) in -cyclodextrin, 65 
ratio coelenterazine:cyclodextrin = 1:50). 
Figure 3 shows the kinetics of light emission from the supernatant 
of the C17.2 cells in the presence of coelenterazine.  
 
Figure 3: Time-profile of the bioluminescence occurring from gLuc: 100 70 
µL of supernatant from the medium, in which gLuc transfected neural 
stem cells (NSC) have been grown for 24h, 8 µl of coelenterazine  
(1mg/mL) or 8 µl of coelenterazine in -cyclodextrin, ratio 
coelenterazine:cyclodextrin = 1:50). 
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Secreted gLuc is very stable under the conditions reported here, 
as indicated by first-order kinetics after the addition of 
coelenterazine. It is noteworthy that secreted gLuc retained its 
catalytic activity for up to 1 year at 195K and for up to one month 
at 277K. The observed bisexponential first order kinetics can be 5 
explained by the heterogeneity of the supernatant from culturing 
gLuc secreting NCS’s. Although coelenterazine (COEL) is more 
hydrophobic (log P = 3.40628) than its’ -cyclodextrin 
(COEL_CD) adduct (log P = -1.228), the addition of free COEL 
resulted in a higher photon flux within 90min. after mixing (total 10 
measured photon flux: 1.370.05 x 1012 photons (COEL) vs. 
9.90 0.05 x 1011 photons (COEL_CD). The crossover between 
the bioluminescence decay of COEL and the COEL-CD was 
observed after 2535s at low photon flux (1.083 x 108 photons s-1). 
In spite of its higher hydrophobicity, free COEL is soluble in our 15 
culture medium at a concentration of 1.75 x 10-8 mol. We 
attribute its higher efficiency of bioluminescence to the fact that 
only free COEL reacts with gLuc. Therefore, the catalytic activity 
of gLuc depends on the dissociation of the supramolecular 
COEL-CD complex. The half-lives of the gLuc catalyzed bio-20 
luminescence of COEL were determined to be 263s   10s (k1 = 
0.002627 s-1) and 1547s  73 s (k2 = 0.000448 s-1) (see SI). For 
the COEL-CD complex, we have obtained 175s   8s (k1 = 
0.003961 s-1) and 2278s  88 s (k2 = 0.000304 s-1) under 
identical conditions. 25 
 
The maximal photon total flux, as measured by an IVIS® Lumina 
Live Imaging device (Caliper Life Sciences) and calculated by 
integrating Figure 3 was 1.368 0.005 x 1012 photons. However, 
the detection geometry of the IVIS system does not permit the 30 
straightforward calculation of bioluminescence conversion 
efficiencies. 1.05 x 1016 molecules of coelenterazine were added 
to the well. Only 0.026% of coelenterazine molecules emitted 
photons that reached the IVIS detection system. Considering the 
IVIS geometry and depending on assumptions for scattering and 35 
self-absorption, the coelenterazine to bioluminescence conversion 
efficiency within 90 min. is approximately 10-50 times higher. 
Gaussia-Luciferase Based Photodynamic Therapy of Mouse 
Melanoma Cells 
We have used the supernatant from gLuc-expressing neural stem 40 
cells (NSCs) to study the photodynamic effect of protoporphyrin 
IX on B16F10 (mouse melanoma) cells. gLuc expressing NSCs 
(5 x 104 cells) were suspended in 1.0ml of their growth medium. 
The B16F10 cells were incubated at 310K with 5% CO2 for 24 
hours, after which ALA (2 mMol) was added. ALA is the 45 
substrate for the biosynthesis of protoporphyrin IX (PpIX) in the 
mitochondria of the cancer cells. Twenty four hours after 
changing the aqueous buffer to the supernatant from culturing the 
gLuc transfected NSCs, coelenterazine (8g/l) was added as 
water-soluble -cyclodextrin-complex. After addition of 50 
coelenterazine, viable cancer cell numbers were analyzed over a 
36 hours period using an MTT assay.29 All experiments were 
done in triplicate and repeated at least three times. The results are 
shown in Figure 4 (12h after treatment), Figure 5 (24h after 
treatment) and Figure 6 (36h after treatment). To distinguish the 55 
effect of this photodynamic therapy system on B16F10 cell 
viability and cytotoxic/growth augmenting effects that occur in 
the dark, the following control groups were used: 1) B16F10 cells 
(no treatment); 2) B16F10 cells in the presence of ALA 
(aminolevulinic acid); 3) B16F10 cells in the presence of 60 
coelenterazine; 4) B16F10 cells in the presence of coelenterazine 
and gLuc (=bioluminescence). The treatment group consisted of 
B16F10 cells that were cultured in the presence of gLuc, ALA 
(2mmol L-1) and coelenterazine (8g/100 L-1). 
Figure 4: Effect on B16F10 melanoma cell viability of control cells (no 65 
treatment), ALA (aminolevulinic acid) alone, coelenterazine alone, 
coelenterazine and NSC/gLuc (=bioluminescence), or full treatment 
(NSC/gLuc, ALA (2mmol L-1), coelenterazine (8g/100 µL medium)),                  
12h after treatment. 
 70 
Figure 4 indicates that ALA may be able to boost the cancer 
growth, when given alone. ALA is a precursor of porphyrin, 
heme, and bile pigments, and it is metabolized into 
protoporphyrin IX (PpIX) in the course of heme synthesis.30 The 
autofluorescence of PpIX and heme is known to be a predictor of 75 
cancer development, because the biosynthesis of porphyrins is 
upregulated in many cancers.31-33 It is apparent that enhanced 
biosynthesis of porphyrins in B16F10 melanoma cells due to the 
presence of the precursor ALA increases the melanoma cell 
growth.   Porphyrins are essential molecules within cells and have 80 
multiple roles in essential cellular processes such as the 
mitochondrial electron transport chain, free-radical detoxification, 
and metabolic activity. Therefore, upregulating porphyrin 
biosynthesis is beneficial for the cancer cell.34 
Coelenteramide, which is formed from coelenterazine through 85 
enzymatic and non-enzymatic oxidation17-19 (see Scheme 2), 
shows discernible cell toxicity. The addition of gLuc apparently 
does not significantly increase this toxicity. This finding clearly 
demonstrated that the blue light emitted by the COEL/gLuc 
system does not harm the B16F10 cells, although the black 90 
melanomas are able to absorb the light. Apparently, the photon 
flux of the bioluminescence is not high enough to cause 
detectable harm. A detailed ANOVA analysis of these data, 
which is provided in the SI section, clearly indicates that the 
COEL and COEL/gLuc groups cannot be distinguished from the 95 
treatment group 12h after PDT. 
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Scheme 2: The oxidation of coelenterazine (3) to coelenteramide (4) is 
catalyzed by gLuc. In the absence of gLuc, coelenterazine is slowly 
decomposed (within 48h) in aerated aqueous buffer in the presence of 
three Ca2+ ions. 17-19 
Figure 5: Effect on B16F10 melanoma cell viability of control cells (no 5 
treatment), ALA (aminolevulinic acid) alone, coelenterazine alone, 
coelenterazine and NSC/gLuc (=bioluminescence), or full treatment 
(NSC/gLuc, ALA (2mmol L-1), coelenterazine (8g /100 µLmedium)),                
24h after treatment. 
Figure 5 shows that 24h after treatment, all groups remain 10 
essentially unchanged, except the treatment group, which is at 
that time statistically significantly reduced. This finding can be 
regarded as proof that stem cell based photodynamic therapy is 
really working in vitro. The delayed response of B16F10 
melanoma cells to PDT is an indication of apoptosis as the mode 15 
of cell death.35 It must be noted that an ANOVA analysis of the 
data summarized in Figure 5 indicates that the COEL and 
COEL/gLuc control groups cannot be distinguished from the 
treatment group 24h after PDT.  
 20 
Figure 6: Effect on B16F10 melanoma cell viability of control cells (no 
treatment), ALA (aminolevulinic acid) alone, coelenterazine alone, 
coelenterazine and NSC/gLuc (=bioluminescence), or full treatment 
(NSC/gLuc, ALA     (2mmol L-1), coelenterazine (8g /100 µLmedium)),                 
36h after treatment. 25 
 
Figure 6 shows that the irradiated and non-irradiated mouse 
melanoma cells have recovered from the coelenteramide toxicity 
after 36h. ALA is still beneficial to melanoma growth in vitro. 
However, there is virtually no recovery of the treated group of 30 
cells. This finding is again in agreement with the hypothesis of 
apoptosis as the mode of cell death. It also shows that all 
components of the treatment (ALA, COEL and gLuc) are 
required to result in a lasting treatment effect! As ANOVA 
indicates, 36h after PDT, the treatment group is significantly 35 
different from all other groups (p < 0.001).  
 
Experimental 
The synthesis of aminolevulinic acid (ALA) has been performed 
according to a published procedure.36 This team has developed a 40 
novel synthesis for coelenterazine (COEL).37 Coelenterazine 
(1g/mL) was dissolved in acidified MeOH (5 mmol HCl) under 
Ar and -cyclodextrin (molar ratio 50:1) was added. After the 
mixture had completely dissolved, the solvent was removed in 
high vacuum. The white solid was then dissolved in PBS buffer, 45 
resulting in a coelenterazine concentration of 1g/mL. 
 
gLuc transfection of C17.2 mouse neural stem cells 
The immortalized C17.2 mouse neural stem cells (NSC) have 
been transfected using the pCMV-Gluc-1 plasmid (Cat#202, 50 
humanized Gaussia luciferase with secretory signal) from 
NanoLight Technology, Pinetop, AZ 85935. Due to the secretory 
signal, GLuc is secreted into the cell medium of cultured 
mammalian cells upon expression. NSCs were plated in 24 well 
plates in phenol red free NSC medium (Dulbecco’s modified 55 
Eagle medium (DMEM; Invitrogen, Carlsbad, CA) supplemented 
with 10% fetal bovine serum (FBS; Sigma-Aldrich St. Louis, 
MO), 5% horse serum (Invitrogen), 1% glutamax (Invitrogen), 
and 1% penicillin/streptomycin(Invitrogen)) at 40,000 cells per 
well and incubated at 37 °C for 24 hours. After 24 hours, cells 60 
were at 70-80% confluence. Medium was replaced with fresh 
NSC medium without phenol red. For each well of 24 well plate, 
1 µg of pCMV-Gluc-1 plasmid was diluted in 49 µL serum free 
medium and 2 µL of TurboFectTM in vitro transfection reagent 
(Fermentas, Life Science) was added to the medium and mixed 65 
well by vortexing. After incubation of the plasmid mixture at 25 
°C for 20 minutes, 52 µL of the mixture was added to each well 
and gently mixed by rocking the plate. Then, cells were further 
incubated for 24 hour to allow secretion of gLuc. 
 70 
Bioluminescence from gLuc 
100 L of supernatant from the medium in which gLuc 
transfected neural stem cells (NSC) had been grown for 24h at 
310K, was added to 8 l of coelenterazine (1g/mL) in -
cyclodextrin, ratio coelenterazine:cyclodextrin = 1:50). The 75 
resulting mixture was then imaged using an IVIS Lumina II 
system at 300K.  The bioluminescence spectrum has been 
recorded using an ISA SPEX Fluoromax-2.  
 
Cultures of C17.2 and B16F10 cells (ATCC (Manassas,VA)) 80 
C17.2 cells were cultured in Dulbecco’s modified Eagle medium 
(DMEM; Invitrogen, Carlsbad, CA) with 10% fetal bovine serum 
(FBS Sigma-Aldrich), 5% horse serum (Invitrogen), 1% 
glutamax (Invitrogen), and 1% penicillin/streptomycin 
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(Invitrogen). B16F10 cells were cultered in DMEM( Invitrogen, 
Carlsbad, CA) with 10% FBS (Sigma-Aldrich, St. Louis, MO) 
and 1%penicillin/streptomycin (Invitrogen)with 10% FBS (Fetal 
Bovine Serum), 5% Horse serum, 1% Glutamax, 1% Penstrap. 
Cells were grown overnight as monolayers at a concentration of 5 
20,000 cells/cm2 in 25-cm2 flasks in 5-mL medium at 310K and 
5% CO2. After attaining 70% confluence (after 24h) the growth 
medium was removed. Trypsin EDTA (1mL) was added to 
facilitate the detachment of the cells. After 1 min., 3mL medium 
was added to stop the Trypsin EDTA reaction. The cells were 10 
then replated (at a 1:2 dilution). The conditioned medium (1:5, 
medium from culturing gLuc C17.2 cells:fresh medium of 
B16F10 without phenol red) was used for replacing medium of 
the B16F10 cells. This system was then used for the in-vitro PDT 
experiments. 15 
 
MTT Assay 
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT) was dissolved in PBS at 5.0 mg/mL (MTT reagent). MTT 
solubilization buffer was prepared by dissolving 10% (w/v) 20 
sodium dodecylsulfate and 0.1 M HCl in bidest. water.  To assay 
cell viability, MTT reagent solution 1:10 (v/v, reagent 
solution/cell medium) was added to the cells and incubated at 
310K for 4 h.  Then, MTT solubilization buffer 
(medium/buffer=1:1) was added, followed by overnight 25 
incubation at 310K. The absorbance at 550 nm and 690 nm (as 
background) were measured using a plate reader (Spectra 
MAX190, Molecular Devices). The difference in absorbance 
between the two wavelengths is indicative of the number of live 
cells. 30 
 
Experimental Design 
Statistical analyses of the measured cell viabilities have been 
performed using the program WinSTAT (A-Prompt Corporation, 
Lehigh Valley, PA).38 The means of the experimental groups have 35 
been evaluated to confirm that they meet the normality assumption. 
To evaluate the significance of overall differences in cell viability 
between all in vitro groups, statistical analysis has been 
performed by analysis of variance (ANOVA).   A p-value less 
than 0.01 has been considered as significant.  40 
 
Conclusions 
Addition of media conditioned by Gaussia luciferase- secreting 
neural stem cells generates blue light after the addition of 
coelenterazine that can significantly attenuate B16 melanoma 45 
cells pre-exposed to 5-aminolevulinic acid. The attenuation effect 
was observed at 24 hours after treatment and was most significant 
relative to controls at 36 hours after PDT. 
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